

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

Name of entity	<b>REVA Medical, Inc.</b>
ARBN	<b>146 505 777</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stephen N. Oesterle
Date of last notice	6 February 2018

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	n/a
Date of change	<ul style="list-style-type: none"> <li>17 May 2018</li> </ul>
No. of securities held prior to change	<ul style="list-style-type: none"> <li>330,000 CDIs (equivalent to 33,000 shares of common stock)</li> </ul>
Class	<ul style="list-style-type: none"> <li>CDIs</li> </ul>
Number acquired	<ul style="list-style-type: none"> <li>86,917 options, each to acquire 1 share of common stock at an exercise price of US\$1.96 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> </ul>
Number disposed	<ul style="list-style-type: none"> <li>None</li> </ul>
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ul style="list-style-type: none"> <li>None</li> </ul>
No. of securities held after change	<ul style="list-style-type: none"> <li>330,000 CDIs (equivalent to 33,000 shares of common stock)</li> <li>86,917 options, each to acquire 1 share of common stock at an exercise price of US\$1.96 per share, under the Company's Amended and Restated 2010 Equity Incentive Plan</li> </ul>

+ See chapter 19 for defined terms.

## Appendix 3Y Change of Director's Interest Notice

---

<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<ul style="list-style-type: none"> <li>Grant of options to purchase common stock</li> </ul>
---	---

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

---

+ See chapter 19 for defined terms.